The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Bacteriophages as potential new therapeutics to replace or supplement antibiotics
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sulakvelidze, A., Alavidze, Z., & Morris, J. G. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.3.649-659.2001 · Cited by 1,566
Wright, A., Hawkins, C. H., Änggård, E. E., & Harper, D. R. (2009) · Clinical Otolaryngology · doi:10.1111/j.1749-4486.2009.01973.x · Cited by 864
Phage Therapy in Clinical Practice: Treatment of Human Infections
Kutter, E., De Vos, D., Gvasalia, G., Alavidze, Z., Gogokhia, L., Kuhl, S., & Abedon, S. (2010) · Current Pharmaceutical Biotechnology · doi:10.2174/138920110790725401 · Cited by 670
Bacteriophages: Biology and Applications
Silver, S., & Baylor, M. (2006) · Microbe Magazine · doi:10.1128/microbe.1.151.1 · Cited by 570
Merabishvili, M., Pirnay, J.-P., Verbeken, G., Chanishvili, N., Tediashvili, M., Lashkhi, N., Glonti, T., Krylov, V., Mast, J., Van Parys, L., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004944 · Cited by 511
Phage-Antibiotic Synergy (PAS): β-Lactam and Quinolone Antibiotics Stimulate Virulent Phage Growth
Comeau, A., Tétart, F., Trojet, S. N., Prère, M. F., & Krisch, H. M. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000799 · Cited by 488
Phage Choice, Isolation, and Preparation for Phage Therapy
Gill, J., & Hyman, P. (2010) · Current Pharmaceutical Biotechnology · doi:10.2174/138920110790725311 · Cited by 441
Phage therapy experience at the Eliava Institute
Kutateladze, M., & Adamia, R. (2008) · Médecine et Maladies Infectieuses · doi:10.1016/j.medmal.2008.06.023 · Cited by 258
Self-citationVancomycin‐Resistant Enterococci: Mechanisms and Clinical Observations
Gold, H. S. (2001) · Clinical Infectious Diseases · doi:10.1086/321815 · Cited by 258
Goodridge, L. D. (2010) · Current Pharmaceutical Biotechnology · doi:10.2174/138920110790725348 · Cited by 155
Cited by
Phage Therapy: A Renewed Approach to Combat Antibiotic-Resistant Bacteria
Kortright, K. E., Chan, B. K., Koff, J. L., & Turner, P. E. (2019) · Cell Host & Microbe · doi:10.1016/j.chom.2019.01.014 · Cited by 1,212
Phage therapy: An alternative to antibiotics in the age of multi-drug resistance
Lin, D. M., Koskella, B., & Lin, H. C. (2017) · World Journal of Gastrointestinal Pharmacology and Therapeutics · doi:10.4292/wjgpt.v8.i3.162 · Cited by 1,135
Pros and cons of phage therapy
Loc-Carrillo, C., & Abedon, S. T. (2011) · Bacteriophage · doi:10.4161/bact.1.2.14590 · Cited by 1,020
Bacteriophage therapy: a potential solution for the antibiotic resistance crisis
Golkar, Z., Bagasra, O., & Pace, D. G. (2014) · The Journal of Infection in Developing Countries · doi:10.3855/jidc.3573 · Cited by 593
Bacteriophage-encoded depolymerases: their diversity and biotechnological applications
Pires, D. P., Oliveira, H., Melo, L. D. R., Sillankorva, S., & Azeredo, J. (2016) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-015-7247-0 · Cited by 517
Escherichia coli in Europe: An Overview
Allocati, N., Masulli, M., Alexeyev, M., & Di Ilio, C. (2013) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph10126235 · Cited by 471
Advantages and Limitations of Bacteriophages for the Treatment of Bacterial Infections
Principi, N., Silvestri, E., & Esposito, S. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00513 · Cited by 454
Yehl, K., Lemire, S., Yang, A. C., Ando, H., Mimee, M., Torres, M. D. T., de la Fuente-Nunez, C., & Lu, T. K. (2019) · Cell · doi:10.1016/j.cell.2019.09.015 · Cited by 437
Genetically Engineered Phages: a Review of Advances over the Last Decade
Pires, D. P., Cleto, S., Sillankorva, S., Azeredo, J., & Lu, T. K. (2016) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00069-15 · Cited by 427
The role of microbial biofilms in prosthetic joint infections: A review
Gbejuade, H. O., Lovering, A. M., & Webb, J. C. (2015) · Acta Orthopaedica · doi:10.3109/17453674.2014.966290 · Cited by 418
Phage Therapy—History from Twort and d'Herelle Through Soviet Experience to Current Approaches
Chanishvili, N. (2012) · Advances in Virus Research · doi:10.1016/b978-0-12-394438-2.00001-3 · Cited by 407
Clinical Aspects of Phage Therapy
Międzybrodzki, R., Borysowski, J., Weber-Dąbrowska, B., Fortuna, W., Letkiewicz, S., Szufnarowski, K., Pawełczyk, Z., Rogóż, P., Kłak, M., Wojtasik, E., et al. (2012) · Advances in Virus Research · doi:10.1016/b978-0-12-394438-2.00003-7 · Cited by 373
More Is Better: Selecting for Broad Host Range Bacteriophages
Ross, A., Ward, S., & Hyman, P. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.01352 · Cited by 367
The factors affecting effectiveness of treatment in phages therapy
Ly-Chatain, M. H. (2014) · Frontiers in Microbiology · doi:10.3389/fmicb.2014.00051 · Cited by 331
Targeting the “Cytokine Storm” for Therapeutic Benefit
D'Elia, R. V., Harrison, K., Oyston, P. C., Lukaszewski, R. A., & Clark, G. C. (2013) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00636-12 · Cited by 324
Kleinheinz, K. A., Joensen, K. G., & Larsen, M. V. (2014) · Bacteriophage · doi:10.4161/bact.27943 · Cited by 322
Bacteriophage therapy against Pseudomonas aeruginosa biofilms: a review
Chegini, Z., Khoshbayan, A., Taati Moghadam, M., Farahani, I., Jazireian, P., & Shariati, A. (2020) · Annals of Clinical Microbiology and Antimicrobials · doi:10.1186/s12941-020-00389-5 · Cited by 321
The next generation of bacteriophage therapy
Lu, T. K., & Koeris, M. S. (2011) · Current Opinion in Microbiology · doi:10.1016/j.mib.2011.07.028 · Cited by 312
Evolutionary Rationale for Phages as Complements of Antibiotics
Torres-Barceló, C., & Hochberg, M. E. (2016) · Trends in Microbiology · doi:10.1016/j.tim.2015.12.011 · Cited by 308
Morello, E., Saussereau, E., Maura, D., Huerre, M., Touqui, L., & Debarbieux, L. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016963 · Cited by 275
Law, N., Logan, C., Yung, G., Furr, C.-L. L., Lehman, S. M., Morales, S., Rosas, F., Gaidamaka, A., Bilinsky, I., Grint, P., et al. (2019) · Infection · doi:10.1007/s15010-019-01319-0 · Cited by 260
Bacteriophages in Natural and Artificial Environments
Batinovic, S., Wassef, F., Knowler, S. A., Rice, D. T. F., Stanton, C. R., Rose, J., Tucci, J., Nittami, T., Vinh, A., Drummond, G. R., et al. (2019) · Pathogens · doi:10.3390/pathogens8030100 · Cited by 253
Towards synthetic biological approaches to resource utilization on space missions
Menezes, A. A., Cumbers, J., Hogan, J. A., & Arkin, A. P. (2015) · Journal of The Royal Society Interface · doi:10.1098/rsif.2014.0715 · Cited by 147
Crosstalk between gut microbiota and sepsis
Niu, M., & Chen, P. (2021) · Burns & Trauma · doi:10.1093/burnst/tkab036 · Cited by 69
Bacteriophage Therapy: Discovery, Development, and FDA Approval Pathways
Niazi, S. K. (2025) · Pharmaceuticals · doi:10.3390/ph18081115 · Cited by 56
Bacteriophages as Targeted Therapeutic Vehicles: Challenges and Opportunities
Venkataraman, S., Shahgolzari, M., Yavari, A., & Hefferon, K. (2025) · Bioengineering · doi:10.3390/bioengineering12050469 · Cited by 38
Metadata
- Authors
- Kutateladze, M., & Adamia, R.
- Venue
- Trends in Biotechnology
- Publisher
- Elsevier BV
- Published
- 2010-12
- Volume
- 28
- Issue
- 12
- Pages
- 591-595
- ISSN
- 0167-7799 (ISSN-L)
- OpenAlex
- W2118781326
- Cited by
- 483
- References
- 14
- FWCI
- 2.91
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.